Technology & AI

OpenAI purchases Orchestra Bio, a firm coordinating drug development

Orchestra's team and technology will go into OpenAI's Rosalind life sciences model and related Workbench tool.

By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .

This story is no longer being updated. It reflects reporting up to .

What happened

The AI company bought Orchestra Bio, a platform that tracks drug development timelines and delays. OpenAI plans to fold Orchestra's staff and technology into Rosalind, its life sciences AI model. The related Rosalind Workbench tool is intended to help scientists plan experiments and analyze outcomes.

Why it matters

The deal raises oversight questions for pharmaceutical teams. It reflects AI developers competing to change how medicines are discovered.

Timeline

  1. Oct 20, 3:32 PM ET: OpenAI acquires Orchestra Bio, whose platform tracks drug development timelines.
  2. Oct 20, 4:35 PM ET: OpenAI says it will add Orchestra's team and technology to Rosalind and the Workbench tool.
  3. Oct 21, 10:47 AM ET: OpenAI announces the deal on Tuesday alongside a ChatGPT feature that lets users lock conversations.

Coverage

More on this story

More from Technology & AI

All Technology & AI news · Technology & AI story archive